Wenhui Wei1, Chunshen Pan2, Lin Xie3, Onur Baser4. 1. Sanofi U.S., Inc., Bridgewater, New Jersey. 2. PRO Unlimited, Boca Raton, Florida. 3. STATinMED Research, Inc., Ann Arbor, Michigan. 4. University of Michigan, Ann Arbor, Michigan.
Abstract
OBJECTIVE: To evaluate real-world treatment persistence among patients with type 2 diabetes mellitus (T2DM) initiating treatment with insulin. METHODS: Patient-level data were pooled from 3 previously published observational retrospective studies evaluating patients with T2DM who were previously on oral antidiabetic drugs (OADs) and initiated with a basal analog insulin (insulin glargine or insulin detemir). Treatment persistence was defined as remaining on the study drug during the 1-year follow-up period without discontinuation or switching after study drug initiation. Analyses were conducted to identify baseline factors associated with persistence with insulin therapy and to estimate the association between insulin treatment persistence and patients' clinical and economic outcomes during the follow-up period. RESULTS: A total of 4,804 patients with T2DM (insulin glargine: n = 4,172, insulin detemir: n = 632) were included. The average insulin persistence rate over the 1-year follow-up period was 65.0%. A significantly higher persistence rate was associated with older age, initiation with insulin glargine using either disposable pens or vial-and-syringe, and with baseline exenatide or sitagliptin use. Higher insulin treatment persistence was also associated with lower hemoglobin A1c (A1C) at follow-up, a greater reduction in A1C from baseline, and lower health care utilization. CONCLUSION: In real-world settings, treatment persistence among patients with T2DM initiating basal insulin is influenced by the type of insulin and patient factors. Greater insulin treatment persistence is linked to improved clinical outcomes and reduced health care utilization.
OBJECTIVE: To evaluate real-world treatment persistence among patients with type 2 diabetes mellitus (T2DM) initiating treatment with insulin. METHODS:Patient-level data were pooled from 3 previously published observational retrospective studies evaluating patients with T2DM who were previously on oral antidiabetic drugs (OADs) and initiated with a basal analog insulin (insulin glargine or insulin detemir). Treatment persistence was defined as remaining on the study drug during the 1-year follow-up period without discontinuation or switching after study drug initiation. Analyses were conducted to identify baseline factors associated with persistence with insulin therapy and to estimate the association between insulin treatment persistence and patients' clinical and economic outcomes during the follow-up period. RESULTS: A total of 4,804 patients with T2DM (insulinglargine: n = 4,172, insulin detemir: n = 632) were included. The average insulin persistence rate over the 1-year follow-up period was 65.0%. A significantly higher persistence rate was associated with older age, initiation with insulinglargine using either disposable pens or vial-and-syringe, and with baseline exenatide or sitagliptin use. Higher insulin treatment persistence was also associated with lower hemoglobin A1c (A1C) at follow-up, a greater reduction in A1C from baseline, and lower health care utilization. CONCLUSION: In real-world settings, treatment persistence among patients with T2DM initiating basal insulin is influenced by the type of insulin and patient factors. Greater insulin treatment persistence is linked to improved clinical outcomes and reduced health care utilization.
Authors: Julie C Lauffenburger; Jennifer Lewey; Saira Jan; Sagar Makanji; Christina A Ferro; Alexis A Krumme; Jessica Lee; Roya Ghazinouri; Nancy Haff; Niteesh K Choudhry Journal: JAMA Netw Open Date: 2019-03-01
Authors: Jennifer Lewey; Wenhui Wei; Julie C Lauffenburger; Sagar Makanji; Alan Chant; Jeff DiGeronimo; Gina Nanchanatt; Saira Jan; Niteesh K Choudhry Journal: BMJ Open Date: 2017-10-30 Impact factor: 2.692